Zak Mir talks to Adrian Kinkaid, CEO Fusion Antibodies, as the Early Discovery Contract Research Organisation specialising in pre-clinical antibody discovery, announces its unaudited interim results for the six months ended 30 September 2023 and provides an update on recent commercial progress.
Author
